The Dyskinesia drugs in development market research report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Dyskinesia. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Dyskinesia and features dormant and discontinued products.

GlobalData tracks 80 drugs in development for Dyskinesia by 63 companies/universities/institutes. The top development phase for Dyskinesia is preclinical with 37 drugs in that stage. The Dyskinesia pipeline has 75 drugs in development by companies and five by universities/ institutes. Some of the companies in the Dyskinesia pipeline products market are: Contera Pharma, Jazz Pharmaceuticals and Neurocrine Biosciences.

The key targets in the Dyskinesia pipeline products market include Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25), Synaptic Vesicular Amine Transporter (Monoamine Transporter or Solute Carrier Family 18 Member 2 or Vesicular Amine Transporter 2 or VAT2 or SLC18A2), and Glutamate Ionotropic Receptor NMDA Type Subunit (NMDAR or GRIN).

The key mechanisms of action in the Dyskinesia pipeline product include Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25) Inhibitor with eight drugs in Pre-Registration. The Dyskinesia pipeline products include 11 routes of administration with the top ROA being Oral and five key molecule types in the Dyskinesia pipeline products market including Small Molecule, and Protein.

Dyskinesia overview

Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing, and tongue thrusting. The disease can be controlled by healthy life style and medication.

For a complete picture of Dyskinesia’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.